AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUL 1 - (NewsRx.com & NewsRx.net) -- Bcl-2 expression decreases in endometrial carcinomas.
"Our aim was to compare the results of bcl-2 expression in endometrial carcinoma with clinicopathological prognostic factors along with p53 accumulation. In addition, p53 expression was compared to different subtypes of endometrial carcinoma," scientists writing in the Journal of Experimental & Clinical Cancer Research report.
"Immunohistochemical staining was pet-formed on formalin-fixed, paraffin embedded tissue sections by using Bcl-2 Supersensitive Mouse Anti-Bcl-2 Oncoprotein (Biogenex AM287-5M) for bcl-2 immunostaining and Supersensitive Mouse Anti-p53 Suppressor Gene Product (1801) (Biogenex AM 240-5M) for p53 immunostaining.
"Nine out of 9 cases of proliferative endometrium, 515 cases of endometrial hyperplasia without atypia, 515 cases with atypia, and 21/35 cases of endometrial carcinoma showed bcl-2 protein expression. Bcl2 expression was not related to age, surgical stage, or histopathological features, nor was there an inverse correlation between bcl-2 and p53 expression in endometrial carcinoma. p53 expression was detected in 3/4 cases of serous papillary carcinoma," said S. Erkanli and colleagues, "whereas only 5/31 cases of endometrioid carcinoma showed p53 expression."
...
Source: HighBeam Research, Bcl-2 expression decreases in endometrial carcinomas.